Resectable metastatic melanoma
Showing 1 - 25 of >10,000
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID
Recruiting
- Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
- +2 more
- Ipilimumab
- +3 more
-
Atlanta, GeorgiaEmory University Hospital/Winship Cancer Institute
Feb 11, 2022
Metastatic Melanoma, Metastasis to Brain Trial in Tampa, Houston (Nivolumab, Ipilimumab, Nivolumab + Relatlimab)
Recruiting
- Metastatic Melanoma
- Metastasis to Brain
- Nivolumab
- +3 more
-
Tampa, Florida
- +1 more
Jan 30, 2023
Melanoma Stage III, Melanoma Stage IV Trial in Amsterdam (T-VEC)
Recruiting
- Melanoma Stage III
- Melanoma Stage IV
-
Amsterdam, NH, NetherlandsAntoni van Leeuwenhoek ziekenhuis
Feb 11, 2022
metAsTatI? melanOma Treated With dabrafeNib and trAmetinib in
Recruiting
- Melanoma Stage III
- +2 more
-
Barnaul, Alatai, Russian Federation
- +14 more
May 29, 2022
Melanoma Stage III Trial in North Sydney (Pembrolizumab, Lenvatinib)
Recruiting
- Melanoma Stage III
-
North Sydney, New South Wales, AustraliaMelanoma Institute Australia
Oct 26, 2022
Melanoma Stage III Trial in Shanghai (Toripalimab combined with Temozolomide)
Not yet recruiting
- Melanoma Stage III
- Toripalimab combined with Temozolomide
-
Shanghai, ChinaFudan University Shanghai Cancer Center
Apr 23, 2023
Unresectable or Metastatic Melanoma Trial in Russian Federation (Prolgolimab)
Active, not recruiting
- Unresectable or Metastatic Melanoma
-
Arkhangel'sk, Russian Federation
- +5 more
Mar 23, 2023
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 Trial in Shanghai (Endostar,
Recruiting
- Clinical Stage III Cutaneous Melanoma AJCC v8
- Clinical Stage IV Cutaneous Melanoma AJCC v8
-
Shanghai, ChinaFudan University Shanghai Cancer Center
Jun 17, 2023
Melanoma Trial in Sydney, Wollstonecraft, Melbourne (Dabrafenib, Trametinib, Pembrolizumab)
Active, not recruiting
- Melanoma
- Dabrafenib
- +2 more
-
Sydney, New South Wales, Australia
- +2 more
Apr 4, 2022
Tumor Skin, Metastatic Melanoma, Melanoma Trial in Orlando, Louisville (OBX-115)
Active, not recruiting
- Tumor Skin
- +2 more
- OBX-115
-
Orlando, Florida
- +1 more
Sep 28, 2023
Metastatic Uveal Melanoma Trial in Tampa (ZIV-Aflibercept, Cemiplimab)
Recruiting
- Metastatic Uveal Melanoma
-
Tampa, FloridaMoffitt Cancer Center
Nov 2, 2023
Melanoma Trial in Salt Lake City (Nivolumab, HF10)
Terminated
- Melanoma
-
Salt Lake City, UtahHuntsman Cancer Institute
Jun 9, 2022
Uveal Melanoma Trial in Pittsburgh (Tebentafusp)
Not yet recruiting
- Uveal Melanoma
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Oct 5, 2023
Metastatic Uveal Melanoma Trial in Grand Rapids (IDE196, Crizotinib, Pembrolizumab)
Recruiting
- Metastatic Uveal Melanoma
- IDE196
- +5 more
-
Grand Rapids, MichiganThe Cancer and Hematology Centers
Aug 14, 2023
Uveal Melanoma, Melanoma, Metastatic Uveal Melanoma Trial in Harrison, New York (Lifileucel (LN-144))
Recruiting
- Uveal Melanoma
- +3 more
- Lifileucel (LN-144)
-
Harrison, New York
- +1 more
Nov 8, 2022
Immunotherapy in Patients With Metastatic Melanoma
Not yet recruiting
- Metastatic Melanoma
- data collection
- (no location specified)
Nov 28, 2022
Healthcare Resource Utilization and Costs in Metastatic Melanoma
Terminated
- Metastatic Melanoma
-
East Hanover, New JerseyNovartis Investigational Site
Apr 27, 2023
Metastatic Melanoma, Head and Neck Squamous Cell Carcinoma Trial in Portland (GB1211, Pembrolizumab, Placebo)
Not yet recruiting
- Metastatic Melanoma
- Head and Neck Squamous Cell Carcinoma
- GB1211
- +2 more
-
Portland, OregonProvidence Portland Medical Center
Jun 19, 2023
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma Trial in
Not yet recruiting
- Clinical Stage III Cutaneous Melanoma AJCC v8
- +4 more
- Rigosertib
- +4 more
-
Nashville, TennesseeVanderbilt University/Ingram Cancer Center
Feb 28, 2023
Uveal Melanoma Trial in Nice, Paris (Supportive care visit with questionnaires, Oncological standard visit)
Recruiting
- Uveal Melanoma
- Supportive care visit with questionnaires
- Oncological standard visit
-
Nice, France
- +1 more
Jan 19, 2023